In short
This article examines clinical trials investigating the use of pneumococcal polysaccharide serotype 5 conjugate vaccine, which is part of broader pneumococcal vaccines being studied. These trials aim to evaluate the safety, efficacy, and immune responses of various pneumococcal vaccine formulations in different populations, from infants to older adults. The studies explore aspects such as vaccine effectiveness against pneumonia, co-administration with other vaccines, and long-term protection against pneumococcal disease.
At a glance
- Vaccine Types
- 20-valent pneumococcal conjugate vaccine (PCV20), 13-valent pneumococcal conjugate vaccine (PCV13), investigational pneumococcal vaccines
- Study Populations
- Healthy infants, adults aged 18-64 at increased risk, adults aged 65 and older, patients with specific conditions (e.g., multiple sclerosis, multiple myeloma)
- Primary Objectives
- Safety and tolerability, immunogenicity, efficacy against pneumococcal disease
- Key Outcome Measures
- Antibody levels, opsonophagocytic activity (OPA) titers, adverse events, vaccine effectiveness against pneumonia
- Study Designs
- Randomized controlled trials, open-label studies, test-negative design for effectiveness studies
- Co-administration Studies
- Some trials evaluate co-administration with other vaccines (e.g., RSV vaccine)
- Long-term Assessments
- Several studies include long-term follow-up to assess duration of protection and safety
What is this vaccine?
The pneumococcal polysaccharide serotype 5 conjugated to CRM197 adsorbed on aluminium phosphate vaccine is one component of broader pneumococcal conjugate vaccines like Prevenar 13 and Apexxnar. These vaccines help protect against invasive pneumococcal disease caused by Streptococcus pneumoniae bacteria.
This specific component targets serotype 5 of S. pneumoniae. The vaccine contains parts of the bacterial capsule (polysaccharides) chemically linked (conjugated) to a non-toxic variant of diphtheria toxin called CRM197. This conjugation helps make the vaccine more effective, especially in young children.
How does it work?
The vaccine works by stimulating the immune system to produce antibodies against the capsule of serotype 5 S. pneumoniae. When exposed to the actual bacteria later, these antibodies help the immune system recognize and fight off the infection more quickly.
The CRM197 protein acts as a carrier, helping to enhance the immune response, particularly in infants and young children whose immune systems are still developing. The aluminium phosphate serves as an adjuvant, further boosting the immune response.
Who is it for?
This vaccine component is included in pneumococcal conjugate vaccines approved for:
- Infants and young children
- Adults 65 years and older
- People with certain medical conditions that increase risk of pneumococcal disease
The exact age recommendations and dosing schedules can vary by country and specific vaccine formulation.
How effective is it?
As part of broader pneumococcal conjugate vaccines, this component helps provide protection against invasive pneumococcal disease caused by serotype 5 S. pneumoniae. Clinical trials have shown these vaccines to be highly effective at preventing severe infections like bacteremia and meningitis.
For example, one study found that the 13-valent pneumococcal conjugate vaccine (which includes this serotype 5 component) was 75% effective at preventing invasive pneumococcal disease caused by vaccine serotypes in adults 65 and older.
Safety and side effects
The pneumococcal conjugate vaccines containing this component have been shown to have a good safety profile in clinical trials. Common side effects may include:
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
- Muscle pain
- Fever (more common in children)
Serious allergic reactions are rare but possible. Patients should seek immediate medical attention if they experience symptoms of a severe allergic reaction after vaccination.
How is it given?
This vaccine component is administered as part of a pneumococcal conjugate vaccine given by intramuscular injection, typically in the thigh for infants or the upper arm for older children and adults. The dosing schedule varies by age and specific vaccine:
- Infants usually receive a series of doses at 2, 4, 6, and 12-15 months of age
- Adults 65 and older typically receive a single dose
- People with certain high-risk conditions may need additional doses
Ongoing research
Researchers continue to study pneumococcal conjugate vaccines to assess long-term effectiveness, optimal dosing schedules, and potential for broader protection. Some current areas of investigation include:
- Evaluating the effectiveness of newer 20-valent pneumococcal conjugate vaccines
- Studying co-administration with other vaccines
- Assessing the impact on pneumococcal carriage and herd immunity
- Monitoring for potential serotype replacement
Patients interested in participating in pneumococcal vaccine research may be able to join clinical trials. Your healthcare provider can provide more information about any ongoing studies you may be eligible for.